Skip to content
MedsAcross

Medicine

Bupivacaine 250 mg/50 mL injection

Bupivacaine · Infiltration
Available on requestPrescription onlyUS FDAGeneric name

Bupivacaine 250 mg/50 mL injection is a generic prescription medicine for infiltration use, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C…

Key facts

Active ingredient (INN)
Bupivacaine
Brand
Sold under the generic name
Strength
250 mg/50 mL
Dosage form
Injection
Route
Infiltration
Packs
1 vial of 50 mL
Manufacturer
Onesource Specialty Pharma
Origin register
US FDA, United States
Storage
Store at 20 °C to 25 °C (68 °F to 77 °F), excursions permitted between 15 °C to 30 °C (59 ° F to 86 °F). Protect from light.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
N01BB01 Bupivacaine
HS code (indicative)
3004.90Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
29 January 2026
Identifiers
RxCUI 1012396, 1012404DailyMed set ID 02d0e5f1-5fab-4420-b673-785fd81d7ae2NDC 83270-169Application ANDA091503

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

Packs from every labeler of this generic presentation.

PackCodeLabelerMarketed since
1 vial in 1 carton / 50 mL in 1 vial83270-169-01Onesource Specialty Pharma29 January 2026
1 vial in 1 carton / 50 mL in 1 vial83854-006-01—22 April 2026
25 vial, multi-dose in 1 carton / 50 mL in 1 vial, multi-dose55150-250-50—13 May 2016
10 vial, multi-dose in 1 carton / 50 mL in 1 vial, multi-dose0143-9329-10—11 February 2021
25 vial, multi-dose in 1 tray / 50 mL in 1 vial, multi-dose0409-1163-01—31 March 2005
1 vial, multi-dose in 1 carton / 50 mL in 1 vial, multi-dose71288-726-52—23 June 2023
50 mL in 1 vial, multi-dose70594-119-01—1 August 2023
50 mL in 1 vial, multi-dose51662-1396-1—16 October 2019
25 pouch in 1 case / 1 vial, multi-dose in 1 pouch / 50 mL in 1 vial, multi-dose51662-1588-3—11 July 2022
25 pouch in 1 case / 1 vial, multi-dose in 1 pouch / 50 mL in 1 vial, multi-dose51662-1638-3—2 October 2023
50 mL in 1 vial, multi-dose50090-4516-0—11 September 2019
1 vial, multi-dose in 1 bag / 50 mL in 1 vial, multi-dose0404-9827-50—9 January 2022
1 vial, multi-dose in 1 bag / 50 mL in 1 vial, multi-dose71872-7270-1—21 October 2021
25 vial, multi-dose in 1 carton / 50 mL in 1 vial, multi-dose72603-287-25—16 December 2024
1 vial in 1 carton / 50 mL in 1 vial70069-753-01—29 May 2024
10 vial in 1 carton / 50 mL in 1 vial70069-753-10—30 May 2024
25 vial in 1 carton / 50 mL in 1 vial70069-753-25—27 November 2023

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 3 October 1972Drugs@FDA
EU (EMA)AuthorisedEMA medicines data
India (CDSCO)Not yet confirmed against CDSCO approval lists—
AustriaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BelgiumRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
BulgariaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CroatiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CyprusRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
CzechiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
DenmarkRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
EstoniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FinlandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
FranceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GermanyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
GreeceRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
HungaryRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IcelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
IrelandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
ItalyRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LatviaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LiechtensteinRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LithuaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
LuxembourgRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
MaltaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NetherlandsRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
NorwayRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PolandRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
PortugalRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
RomaniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SlovakiaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SloveniaRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SpainRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
SwedenRegisteredEuropean Medicines Agency (central authorisation)Checked 12 November 2026
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Bupivacaine 250 mg/50 mL injection.

Compare all 4

Other strengths and forms of Bupivacaine

Clinical summary

Bupivacaine is an amide local anesthetic indicated in adults for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures. MedsAcross supplies Bupivacaine for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Bupivacaine

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Bupivacaine 250 mg/50 mL injection for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.